• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    China Resources Pharmaceutical Group (SEHK:3320), Why Is It Getting Fresh Attention Today?

    Simply Wall St·09/05/2026 13:24:50
    語音播報

    China Resources Pharmaceutical Group (SEHK:3320) drew fresh attention after reporting half year 2026 results, with sales of CNY 134,457.58 million and net income of CNY 2,186.63 million ahead of its upcoming earnings call.

    At a latest share price of HK$4.435, China Resources Pharmaceutical Group has seen pressure in the short term, with the 30 day share price return down 8.46% and the year to date share price return down 1.66%, while the 5 year total shareholder return of 26.79% points to much steadier longer term momentum.

    See how China Resources Pharmaceutical Group compares with other healthcare stocks showing solid fundamentals and potential re-rating catalysts in our curated list of solid balance sheet and fundamentals (438 results)

    China Resources Pharmaceutical Group looks like a large, diversified healthcare business with steady half year sales and earnings, yet the share price has been under pressure. So are investors paying a fair price for that profile today?

    Price-to-Earnings of 5.7x: Is It Justified For China Resources Pharmaceutical Group?

    China Resources Pharmaceutical Group is trading on a P/E of 5.7x, which screens as inexpensive next to both its peers and the wider Hong Kong Pharmaceuticals industry.

    The P/E ratio compares the current share price with earnings per share. For a healthcare group that earns the bulk of its revenue from manufacturing and distributing pharmaceutical products across Mainland China, it is a quick way for investors to see how much the market is paying for each unit of current earnings.

    For China Resources Pharmaceutical Group, several data points pull in the same direction. Earnings grew 48.4% over the past year and have risen by 4% per year over the past 5 years, yet the stock trades at 5.7x earnings compared to a peer average of 18.2x and a Hong Kong Pharmaceuticals industry average of 14.4x. Our estimates of good value, based on a fair P/E of 15.1x, indicate that the current market valuation is well below the level the ratio could move toward if sentiment or expectations shifted.

    Investors comparing opportunities across healthcare companies may see this low multiple as a sign that the market is pricing in more caution on future earnings than implied by recent growth. Earnings are also described as high quality. The stock is additionally flagged as trading at good value compared to both peers and the industry overall. It is also trading below an estimate of future cash flow value of HK$30.42 per share against a last close of HK$4.435.

    Explore the SWS fair ratio for China Resources Pharmaceutical Group.

    Result: Price-to-Earnings of 5.7x (UNDERVALUED)

    However, investors in China Resources Pharmaceutical Group still face risks from its ongoing share price weakness and its significant exposure to Mainland China healthcare policy and pricing decisions.

    Find out about the key risks to this China Resources Pharmaceutical Group narrative.

    Another View Using the SWS DCF Model

    The low 5.7x P/E suggests China Resources Pharmaceutical Group is cheap on earnings. The SWS DCF model offers a different lens. It points to a future cash flow value of HK$30.42 per share versus a last close of HK$4.435, which also indicates undervaluation. How much weight do you place on a model like that?

    Look into how the SWS DCF model arrives at its fair value..

    3320 Discounted Cash Flow as at Sep 2026
    3320 Discounted Cash Flow as at Sep 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out China Resources Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Given the mix of cautious and optimistic signals around China Resources Pharmaceutical Group, it makes sense to review the numbers firsthand and decide quickly how that stacks up with your own expectations, starting with the 5 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond China Resources Pharmaceutical Group?

    If China Resources Pharmaceutical Group has sharpened your focus on valuation and quality, do not stop here. Broader research across other stocks can help round out your watchlist.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.